Novonix (NVNXF) Cash & Equivalents (2020 - 2025)

Novonix has reported Cash & Equivalents for 6 years, with the latest figure at $42.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 45.93% year-over-year to $42.6 million; the trailing twelve-month figure through Dec 2025 stood at $42.6 million (down 45.93% YoY), and the FY2025 full-year result was $42.6 million, down 45.93% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $42.6 million, roughly flat from $42.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $189.0 million in Q4 2021, with the low at $42.6 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $95.1 million across 5 years, with a median of $99.0 million in 2022.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 294.3% — and 2024, when it slumped 52.41%.
• Novonix's Cash & Equivalents stood at $189.0 million in 2021, then sank by 47.61% to $99.0 million in 2022, then changed by 0.0% to $99.0 million in 2023, then dropped by 20.52% to $78.7 million in 2024, then slumped by 45.93% to $42.6 million in 2025.
• The last three Cash & Equivalents figures came in at $42.6 million (Q4 2025), $42.6 million (Q2 2025), and $78.7 million (Q4 2024), per Business Quant data.